MedTrace Logo

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

NCT05941715 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-06-06

No results posted yet for this study

Summary

Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab.

Primary objective: To assess the efficacy of faricimab compared to aflibercept in terms of durability at 32 weeks by extending treatment interval in previous high-frequent aflibercept treated nAMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Aflibercept 40 MG/ML

treat-and-extend

DRUG

Faricimab 120 MG/ML

treat-and-extend

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Andreas Wedrich, MD · Department of Ophthalmology, Medical University Graz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-04
Primary Completion
2024-09-25
Completion
2025-02-26

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05941715 on ClinicalTrials.gov